Insider Selling: Gevo CEO Sells 2,023 Shares of Stock (GEVO)
Gevo (NASDAQ:GEVO) CEO Patrick R. Gruber unloaded 2,023 shares of the company’s stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $0.95, for a total value of $1,921.85. Following the completion of the transaction, the chief executive officer now directly owns 385,381 shares of the company’s stock, valued at approximately $366,112. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of analysts have recently weighed in on GEVO shares. Analysts at Cowen and Company cut their price target on shares of Gevo to $1.00 in a research note on Friday, May 16th. Separately, analysts at Zacks downgraded shares of Gevo from an “outperform” rating to a “neutral” rating in a research note on Thursday, May 8th. They now have a $1.30 price target on the stock. Finally, analysts at Zacks upgraded shares of Gevo from a “neutral” rating to an “outperform” rating in a research note on Wednesday, April 9th. They now have a $1.50 price target on the stock.
Gevo (NASDAQ:GEVO) traded up 1.04% on Tuesday, hitting $0.97. The stock had a trading volume of 324,415 shares. Gevo has a 52-week low of $0.73 and a 52-week high of $2.31. The stock has a 50-day moving average of $0.95 and a 200-day moving average of $1.20. The company’s market cap is $65.8 million.
Gevo (NASDAQ:GEVO) last announced its earnings results on Wednesday, May 14th. The company reported ($0.18) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.21) by $0.03. The company had revenue of $0.90 million for the quarter, compared to the consensus estimate of $1.70 million. During the same quarter last year, the company posted ($0.45) earnings per share. Gevo’s revenue was down 74.3% compared to the same quarter last year. On average, analysts predict that Gevo will post $-0.67 earnings per share for the current fiscal year.
Gevo, Inc, is a renewable chemicals and advanced biofuels company. The Company is focused on the development and commercialization of alternatives to petroleum-based products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.